Peptide Therapeutics: Contract API Manufacturing Market- Likely Evolution of the Different Regions

Several industry players have established peptide manufacturing facilities across the world. During our research, we came across North America and Europe emerged as the current manufacturing hub for peptides, as 75% of the total facilities are presently located in these regions. Various companies were found to be involved in the manufacturing of peptide APIs, while few were focused on the manufacturing of peptide FDF. Our analysis also revealed that, some of the companies were involved in the manufacturing of both peptide API and FDF in the same facility.

The key observations on the location of the manufacturing facility have been highlighted below:

• In North America, the US has emerged as the key hub for peptide manufacturing. Examples of players that have manufacturing facilities in the US include (in alphabetical order) Karebay Biochem, Peptide Institute, PolyPeptide and Sekisui Xenotech.
• Within Europe, the UK (22%) and Switzerland (17%) emerged as the key peptide manufacturing hubs. Other prominent locations for peptide manufacturing include Belgium, France, Spain and Sweden. Examples of companies with manufacturing facilities in Europe include (in alphabetical order) Abzena, GP Pharm, piChem and ProvePharm.
• Further, in Asia Pacific, it was observed that most of the manufacturing facilities are located in (in decreasing order of number of manufacturing facilities) China (63%), India (25%), Israel (6%) and Japan (6%). Examples of companies with manufacturing facilities in Asia Pacific include (in alphabetical order) Dr. Reddy Custom Pharma Peptide Institute and ScinoPharm.

The majority (30%) of the CMOs engaged in this domain offer services for the production of cyclic peptides, followed by those manufacturing peptides containing unnatural amino acids (19%) and long / linear peptides (18%). It is worth noting that two players claim to have the necessary capabilities to provide all types of peptide modifications; these are (in alphabetical order) Bio-Synthesis and ChemPartner.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the peptide contract manufacturing market. Based on multiple parameters, such as projected growth of overall peptide-based products market, cost of goods sold and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] distribution scale of operation (preclinical / clinical and commercial) [B] type of synthesis method used [C] end user (small, mid-sized and large / very large), and [D] key geographical regions (North America, Europe, Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The "Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030" report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of therapeutic peptides. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

• A detailed review of the overall landscape of companies offering contract services for manufacturing of peptides, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location of CMO, number and location of their respective facilities, type of peptide synthesis method used, type of peptide modification services offered, peptide purification technology used, and regulatory accreditations / certifications.
• An analysis on the recent developments in the industry, highlighting collaborations, facility expansions, and upcoming peptide synthesis technologies within this domain.

Roots Analysis provides market research and consulting in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis.